The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be us...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4816556?pdf=render |
| _version_ | 1818161918018322432 |
|---|---|
| author | Giulio Disanto Pascal Benkert Johannes Lorscheider Stefanie Mueller Jochen Vehoff Chiara Zecca Simon Ramseier Lutz Achtnichts Oliver Findling Krassen Nedeltchev Ernst-Wilhelm Radue Till Sprenger Christoph Stippich Tobias Derfuss Jean-François Louvion Christian P Kamm Heinrich P Mattle Christoph Lotter Renaud Du Pasquier Myriam Schluep Caroline Pot Patrice H Lalive Özgür Yaldizli Claudio Gobbi Ludwig Kappos Jens Kuhle SMSC Scientific Board |
| author_facet | Giulio Disanto Pascal Benkert Johannes Lorscheider Stefanie Mueller Jochen Vehoff Chiara Zecca Simon Ramseier Lutz Achtnichts Oliver Findling Krassen Nedeltchev Ernst-Wilhelm Radue Till Sprenger Christoph Stippich Tobias Derfuss Jean-François Louvion Christian P Kamm Heinrich P Mattle Christoph Lotter Renaud Du Pasquier Myriam Schluep Caroline Pot Patrice H Lalive Özgür Yaldizli Claudio Gobbi Ludwig Kappos Jens Kuhle SMSC Scientific Board |
| author_sort | Giulio Disanto |
| collection | DOAJ |
| description | The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be used to develop prognostic indicators and biomarkers of disease evolution and therapeutic response. The Swiss MS Cohort (SMSC) is a prospective observational study performed across seven Swiss MS centers including patients with MS, clinically isolated syndrome (CIS), radiologically isolated syndrome or neuromyelitis optica. Neurological and radiological assessments and biological samples are collected every 6-12 months. We recruited 872 patients (clinically isolated syndrome [CIS] 5.5%, relapsing-remitting MS [RRMS] 85.8%, primary progressive MS [PPMS] 3.5%, secondary progressive MS [SPMS] 5.2%) between June 2012 and July 2015. We performed 2,286 visits (median follow-up 398 days) and collected 2,274 serum, plasma and blood samples, 152 cerebrospinal fluid samples and 1,276 brain MRI scans. 158 relapses occurred and expanded disability status scale (EDSS) scores increased in PPMS, SPMS and RRMS patients experiencing relapses. Most RRMS patients were treated with fingolimod (33.4%), natalizumab (24.5%) or injectable DMDs (13.6%). The SMSC will provide relevant information regarding DMDs efficacy and safety and will serve as a comprehensive infrastructure available for nested research projects. |
| first_indexed | 2024-12-11T16:25:24Z |
| format | Article |
| id | doaj.art-5c7baa1ec4e24df999173aed779eb920 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T16:25:24Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-5c7baa1ec4e24df999173aed779eb9202022-12-22T00:58:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e015234710.1371/journal.pone.0152347The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.Giulio DisantoPascal BenkertJohannes LorscheiderStefanie MuellerJochen VehoffChiara ZeccaSimon RamseierLutz AchtnichtsOliver FindlingKrassen NedeltchevErnst-Wilhelm RadueTill SprengerChristoph StippichTobias DerfussJean-François LouvionChristian P KammHeinrich P MattleChristoph LotterRenaud Du PasquierMyriam SchluepCaroline PotPatrice H LaliveÖzgür YaldizliClaudio GobbiLudwig KapposJens KuhleSMSC Scientific BoardThe mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be used to develop prognostic indicators and biomarkers of disease evolution and therapeutic response. The Swiss MS Cohort (SMSC) is a prospective observational study performed across seven Swiss MS centers including patients with MS, clinically isolated syndrome (CIS), radiologically isolated syndrome or neuromyelitis optica. Neurological and radiological assessments and biological samples are collected every 6-12 months. We recruited 872 patients (clinically isolated syndrome [CIS] 5.5%, relapsing-remitting MS [RRMS] 85.8%, primary progressive MS [PPMS] 3.5%, secondary progressive MS [SPMS] 5.2%) between June 2012 and July 2015. We performed 2,286 visits (median follow-up 398 days) and collected 2,274 serum, plasma and blood samples, 152 cerebrospinal fluid samples and 1,276 brain MRI scans. 158 relapses occurred and expanded disability status scale (EDSS) scores increased in PPMS, SPMS and RRMS patients experiencing relapses. Most RRMS patients were treated with fingolimod (33.4%), natalizumab (24.5%) or injectable DMDs (13.6%). The SMSC will provide relevant information regarding DMDs efficacy and safety and will serve as a comprehensive infrastructure available for nested research projects.http://europepmc.org/articles/PMC4816556?pdf=render |
| spellingShingle | Giulio Disanto Pascal Benkert Johannes Lorscheider Stefanie Mueller Jochen Vehoff Chiara Zecca Simon Ramseier Lutz Achtnichts Oliver Findling Krassen Nedeltchev Ernst-Wilhelm Radue Till Sprenger Christoph Stippich Tobias Derfuss Jean-François Louvion Christian P Kamm Heinrich P Mattle Christoph Lotter Renaud Du Pasquier Myriam Schluep Caroline Pot Patrice H Lalive Özgür Yaldizli Claudio Gobbi Ludwig Kappos Jens Kuhle SMSC Scientific Board The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE |
| title | The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. |
| title_full | The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. |
| title_fullStr | The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. |
| title_full_unstemmed | The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. |
| title_short | The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. |
| title_sort | swiss multiple sclerosis cohort study smsc a prospective swiss wide investigation of key phases in disease evolution and new treatment options |
| url | http://europepmc.org/articles/PMC4816556?pdf=render |
| work_keys_str_mv | AT giuliodisanto theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT pascalbenkert theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT johanneslorscheider theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT stefaniemueller theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT jochenvehoff theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT chiarazecca theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT simonramseier theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT lutzachtnichts theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT oliverfindling theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT krassennedeltchev theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT ernstwilhelmradue theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT tillsprenger theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT christophstippich theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT tobiasderfuss theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT jeanfrancoislouvion theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT christianpkamm theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT heinrichpmattle theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT christophlotter theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT renauddupasquier theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT myriamschluep theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT carolinepot theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT patricehlalive theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT ozguryaldizli theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT claudiogobbi theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT ludwigkappos theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT jenskuhle theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT smscscientificboard theswissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT giuliodisanto swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT pascalbenkert swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT johanneslorscheider swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT stefaniemueller swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT jochenvehoff swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT chiarazecca swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT simonramseier swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT lutzachtnichts swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT oliverfindling swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT krassennedeltchev swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT ernstwilhelmradue swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT tillsprenger swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT christophstippich swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT tobiasderfuss swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT jeanfrancoislouvion swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT christianpkamm swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT heinrichpmattle swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT christophlotter swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT renauddupasquier swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT myriamschluep swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT carolinepot swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT patricehlalive swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT ozguryaldizli swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT claudiogobbi swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT ludwigkappos swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT jenskuhle swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions AT smscscientificboard swissmultiplesclerosiscohortstudysmscaprospectiveswisswideinvestigationofkeyphasesindiseaseevolutionandnewtreatmentoptions |